|
PPT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.08700000006823E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.25669999646072E-08 |
| Normal-vs-Stage2 |
4.118700E-03 |
| Normal-vs-Stage3 |
2.55550000050064E-08 |
| Normal-vs-Stage4 |
2.45359998984895E-09 |
| Stage1-vs-Stage2 |
2.352800E-01 |
| Stage1-vs-Stage3 |
9.310200E-02 |
| Stage1-vs-Stage4 |
5.596400E-02 |
| Stage2-vs-Stage3 |
3.174300E-02 |
| Stage2-vs-Stage4 |
1.128260E-02 |
| Stage3-vs-Stage4 |
5.842800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.32309999517832E-08 |
| Normal-vs-AfricanAmerican |
2.29090000003485E-06 |
| Normal-vs-Asian |
1.152710E-04 |
| Caucasian-vs-AfricanAmerican |
2.594000E-01 |
| Caucasian-vs-Asian |
4.381000E-01 |
| AfricanAmerican-vs-Asian |
8.978000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.81055999999291E-05 |
| Normal-vs-Female |
1.35769999687341E-08 |
| Male-vs-Female |
2.464200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.12519999773531E-08 |
| Normal-vs-Age(41-60Yrs) |
4.69769999567049E-08 |
| Normal-vs-Age(61-80Yrs) |
1.27220000001316E-06 |
| Normal-vs-Age(81-100Yrs) |
2.644400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.265400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.453400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.578600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.906600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.511000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.358600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.89399999964246E-07 |
| Classical-VS-Follicular |
2.773400E-01 |
| Classical-VS-Other |
7.825200E-01 |
| Classical-VS-Normal |
4.42889999996421E-06 |
| Tall-VS-Follicular |
3.049100E-04 |
| Tall-VS-Other |
1.668240E-01 |
| Tall-VS-Normal |
1.71473946153355E-12 |
| Follicular-VS-Other |
9.331800E-01 |
| Follicular-VS-Normal |
2.10469999983864E-07 |
| Other-VS-Normal |
1.961640E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.23029999982749E-07 |
| Normal-vs-N1 |
8.76630000035128E-07 |
| N0-vs-N1 |
2.861000E-01 |
|
|
